Le Lézard
Classified in: Health, Business, Covid-19 virus
Subjects: PDT, INO

Protection Against Infections Remains a Priority Beyond the Pandemic


FinancialBuzz.com News Commentary

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Due to the pandemic's rapid spread earlier last year, the U.S. Environment Protection Agency (EPA) accelerated its review process of submissions by disinfectant manufacturers. The EPA also took steps to avoid supply chain challenges by making the process of obtaining inert ingredients more flexible. It even allowed for some active ingredients listed in List N ? "Disinfectants for Use Against SARS-CoV-2," to be obtained without checking for the agency's approval. Overall, according to data provided by The Business Research Company, the global sterilization equipment and disinfectants market size is expected to grow from USD 7,142.3 Million in 2019 to USD 9,846.9 Million in 2023 at a compound annual growth rate (CAGR) of 8.4%. In 2020, the sterilization equipment market size was valued at USD 8,049.3 Million, and was driven by increased demand for sterilization equipment, disinfectants, and critical care equipment due to the pandemic. OPTEC International, Inc. (OTC: OPTI), Retractable Technologies, Inc. (NYSE: RVP), Senseonics Holdings, Inc. (NYSE: SENS), Chembio Diagnostics, Inc. (NASDAQ: CEMI), Lakeland Industries, Inc. (NASDAQ: LAKE

Additionally, the pandemic has led to an increased awareness of the importance of maintaining hygiene to avoid transmission of pathogens in healthcare facilities and among the general populous. According to data provided by Grand View Research, the global personal protective equipment market size was valued at USD 77.36 Billion in 2020 and is expected to grow at a CAGR of 7.3% from 2020 to 2028. Currently, even though most of the economy is open, many regulations in regards to use of PPEs are still in place.

OPTEC International, Inc. (OTC: OPTI) announced last week breaking news regarding the, "company's subsidiary Z2O territories report Period Ending September 19th, 2021.

The company launched the Z2O pilot program earlier this year in Austin Texas, the results of the "Uber" of cleaning services app and service providers was accepted extremely well and continues to gain momentum and growth.

As promised, the Z2O network soft launch was initiated in San Diego and Miami, alongside expanding the existing operations in Austin, Texas. The initial beta testing results for the period 9/08/21 to 9/19/21 have shown a total of $699,404, and the volume of the break down per location indicated that the volume was in Austin $349.330, the volume in Miami was $175,266 and in San Diego was $174,808.

The results of this beta testing proved to have a huge success. The software and the hardware of the Z2O system withstood this volume and no downtime in the logs. Now that the beta results are in, the company plans on having aggressive expansion plans in the U.S. and in the European nations. The European version is being worked on by the engineers and coming along with a lot of positives.

The Z2O users are asking Z2O for additional "uber" type services other than cleaning, and these services range from home repair projects, plumbing services, electrical services, Pet sitting services, senior care services, and babysitting services. We are looking into all of these opportunities to meet Z2O users' needs and request, to provide them the services they are looking for while maintaining a high level of service delivery with the focus on customer satisfaction.

The company will be announcing additional territory launches throughout the rest of the year."

Retractable Technologies, Inc. (NYSE: RVP) designs, develops, manufactures, and markets safety syringes and other medical products for the healthcare industry in the United States, rest of North and South America, and internationally. Earlier this year the Company announced that it has entered into an amendment to the Technology Investment Agreement (originally awarded on July 1, 2020) with the U.S. government providing $27,365,232 in additional funding. The amendment calls for an increase in existing domestic manufacturing capabilities by a minimum of 50 percent in order to meet ongoing and future U.S. COVID-19 medical countermeasures demands. In order to satisfy this new objective, Retractable is directed to increase U.S. production of 1mL low dead-space safety syringes by installing new assembly lines and further expanding a portion of its facilities in Little Elm, Texas. The scheduled end date for the modification effort is January 31, 2022.

Senseonics Holdings, Inc. (NYSE: SENS) announced this month that the University Hospitals Accountable Care Organization (UHACO) in Cleveland, Ohio has begun offering the Eversense® CGM System to its Medicare enrollees effective early September, 2021. The recent decision to use the Eversense CGM System in eligible patients with type 1 diabetes or type 2 diabetes on insulin shows the commitment of UHACO to facilitate optimal diabetes management for its enrollees. "We are excited to offer Eversense to our ACO patients with diabetes. Supplying tools for effective glucose management allows us to meet the Standards of Care for patients using insulin as outlined by the American Diabetes Association," said Betul Hatipoglu, M.D., Head of Endocrinology and Diabetes at UHACO. "Eversense offers patients choice amongst continuous glucose monitoring devices. The Eversense CGM system delivers industry leading accuracy, an improved patient experience, and an array of unique features that afford people, especially those in the Medicare population, the opportunity to achieve improved health outcomes."

Chembio Diagnostics, Inc. (NASDAQ: CEMIreported last month its launch of commercial distribution of an FDA Emergency Use Authorized, patent pending, rapid point-of-care COVID-19 antigen test for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to Chembio customers across the United States. The SCoV-2 Ag Detecttm Rapid Test, manufactured by InBios International, Inc., is a rapid immunoassay test authorized for use in laboratories with a CLIA waiver certification. It provides results in 20 minutes from a nasal swab and requires no instrumentation. The test can be used for both patients who are suspected of COVID-19 by their healthcare provider within 5 days of symptom onset and for asymptomatic serial testing. "We are excited about the addition of this differentiated product to our menu of COVID-19 assays," said Charles Caso, Vice President of Sales and Marketing for Chembio. "We are now offering U.S. customers SCoV-2 Ag Detecttm, a test for COVID-19 antigens in both symptomatic and asymptomatic populations, as well as Statustm COVID-19/Flu A&B, a product that differentiates flu from COVID-19 using a single nasal swab sample. Our expanded commercial team can now offer testing solutions for CLIA waived settings and work and school settings."

Lakeland Industries, Inc. (NASDAQ: LAKE) manufactures and sells industrial protective clothing and accessories for the industrial and public protective clothing market worldwide. Earlier this month the Company announced financial results for its fiscal 2022 second quarter ended July 31, 2021. Net sales for 2Q22 of $27.5 million, compared with 2Q21 of $35.0 million and 1Q22 of $34.1 million. Charles D. Roberson, President and Chief Executive Officer of Lakeland Industries, stated, "Lakeland's performance improvements are proving to be sustainable as we have again delivered on our margin, expense controls and cash management objectives as reported in our fiscal 2022 second quarter financial results. This performance is even more impressive when considering the significant global business challenges presented in the aftermath of the COVID-19 pandemic last year and more recent, unpredictable waves of outbreaks in the U.S. and Southeast Asia.

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com 

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For optec international, inc. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has been compensated three thousand dollars by cambridge consulting inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

Media Contact:
[email protected] 
+1-877-601-1879
www.FinancialBuzz.com


These press releases may also interest you

at 09:15
Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for the drug substance of Ferring's intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg) for ensuring...

at 09:10
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announces new data from the largest European real-world evidence study (PERSEUS) of Fetroja®/Fetcroja® (cefiderocol), an innovative...

at 09:10
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced that Denis Johnson has joined the company as its new Chief Operating Officer (COO). Denis joins Kindeva to lead global operations for all Kindeva's...

at 09:10
Today, DRUGDOCS® Inc., a leader in delivering authoritative drug information to healthcare professionals, announced the rollout of a significant update to its platform, now featuring advanced AI integration. The DRUGDOCS® platform systematically...

at 09:02
IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating, constipation, and diarrhea. Misunderstood and stigmatized, this condition significantly impacts individuals' quality of life. World IBS Day 2024 includes...

at 09:00
Gentry Health Services and Pleio, Inc. announce their partnership aimed at redefining the landscape of patient experience in specialty pharmacy. The two companies have launched a program to provide peer-to-patient support as patients initiate...



News published on and distributed by: